StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.56+0.05 (+0.67%)

Close on Nov 20, 2026Market cap $43.72MP/E –Yield –

Xilio Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Xilio Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$61.27M. For fiscal 2025 it was -$5.51M. The highest annual figure on record is -$5.51M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$5.51M–
FY2024Dec 31, 2024-$18.41M–
FY2023Dec 31, 2023-$69.11M–
FY2022Dec 31, 2022-$77.59M–
FY2021Dec 31, 2021-$81.85M–
FY2020Dec 31, 2020-$38.28M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.78M–
Q1 FY2026Mar 31, 2026-$22.90M-179.1%
Q4 FY2025Dec 31, 2025-$2.09M–
Q3 FY2025Sep 30, 2025-$17.50M–
Q2 FY2025Jun 30, 2025-$14.88M–
Q1 FY2025Mar 31, 2025$28.96M–
Q4 FY2024Dec 31, 2024-$14.16M–
Q3 FY2024Sep 30, 2024-$13.68M–
Q4 FY2023Dec 31, 2023-$13.43M–
Q3 FY2023Sep 30, 2023-$13.37M–
Q2 FY2023Jun 30, 2023-$16.89M–
Q1 FY2023Mar 31, 2023-$25.42M–
Q4 FY2022Dec 31, 2022-$18.73M–
Q3 FY2022Sep 30, 2022-$20.24M–
Q2 FY2022Jun 30, 2022-$17.53M–
Q1 FY2022Mar 31, 2022-$21.09M–
Q4 FY2021Dec 31, 2021-$17.54M–
Q3 FY2021Sep 30, 2021-$20.83M–
Q2 FY2021Jun 30, 2021-$20.57M–
Q1 FY2021Mar 31, 2021-$22.90M–
Q4 FY2020Dec 31, 2020-$12.81M–

More Xilio Therapeutics figures

See a number that looks wrong?